Abstract
Many adults with current impairing symptoms of attention-deficit/hyperactivity disorder (ADHD) do not report an age at onset before 7 years of age and cannot, therefore, be assigned the full Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), diagnosis of ADHD. We hypothesized that treatment with oral release osmotic system (OROS) methylphenidate (MPH) will be safe and efficacious for the treatment of adults with late-onset ADHD. This was a 6-week, open-label, prospective treatment study of OROS MPH monotherapy in 36 adult patients with late-onset ADHD (onset later than the required 7 years of age) using standardized instruments for diagnosis and a robust oral daily dose of up to 1.3 mg/kg/day. Symptom severity was assessed with the Adult ADHD Investigator Symptom Report Scale (AISRS) and the Clinical Global Impression (CGI) scale. Subjects reported robust current symptoms of ADHD at pre-treatment baseline (11.1+/-2.8 DSM-IV symptoms), but had an atypical mean age at onset of 14.2+/-8.6 years. Treatment with OROS MPH at an average daily dose of 78.2+/-29.4 mg was associated with a statistically and clinically significant reduction in ADHD symptoms relative to baseline as assessed through the AISRS (-...Continue Reading
References
Dec 1, 1976·Archives of General Psychiatry·D R WoodG E Johnson
May 1, 1985·The American Journal of Psychiatry·P H WenderM Ward
Jan 1, 1985·Clinical Neuropharmacology·C T GualtieriC Finley
Nov 1, 1984·Archives of General Psychiatry·J A MattesH Oliver
Jun 1, 1995·Archives of General Psychiatry·T SpencerK Lapey
Oct 25, 2003·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Rachelle BouffardFiorella Iaboni-Kassab
Mar 25, 2004·Biological Psychiatry·Joseph BiedermanElizabeth Cadogen
Apr 6, 2004·The Psychiatric Clinics of North America·Stephen V Faraone
Apr 6, 2004·The Psychiatric Clinics of North America·Larry J SeidmanGeorge Bush
Mar 2, 2005·Biological Psychiatry·Thomas SpencerStephen Faraone
Mar 4, 2006·The American Journal of Psychiatry·Thomas J SpencerAlan J Fischman
Citations
Dec 15, 2006·Current Medical Research and Opinion·Angelo FalluCarin Binder
Oct 1, 2008·Postgraduate Medicine·Anthony L Rostain
Jan 1, 2010·Journal of Central Nervous System Disease·Michael A SopkoBenjamin Chavez
Sep 13, 2017·Journal of Attention Disorders·Yu-Ju Lin, Susan Shur-Fen Gau
Nov 28, 2017·Journal of Child and Adolescent Psychopharmacology·Michael J SilversteinLenard A Adler
Apr 10, 2018·Journal of Attention Disorders·Mary V Solanto
May 15, 2009·Journal of Clinical Psychopharmacology·Lenard A AdlerThomas Spencer
May 27, 2016·The Cochrane Database of Systematic Reviews·Tamir EpsteinMark Weiser
Dec 31, 2010·Journal of Clinical Psychopharmacology·Lenard A AdlerDiane D Harrison
Jun 21, 2008·CNS Spectrums·Timothy E Wilens
Oct 2, 2009·Journal of Attention Disorders·Thomas J SpencerDouglas K Kelsey
May 17, 2012·Attention Deficit and Hyperactivity Disorders·Breno MatteEugenio Horácio Grevet
Oct 15, 2019·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Gagan JoshiJoseph Biederman
Nov 14, 2019·BMC Psychiatry·Sharon SandersJenny Doust
Oct 6, 2006·Expert Opinion on Pharmacotherapy·David Coghill, Sarah Seth
Aug 15, 2014·CNS Drugs·Martin A Katzman, Tia Sternat
Aug 14, 2009·Expert Review of Neurotherapeutics·J Antoni Ramos-QuirogaMiguel Casas
Oct 30, 2008·Current Neurology and Neuroscience Reports·Paul HammernessKatherine Miller